Vertex: Did Management Deliver Investors a Backhanded Slap?
September 16, 2016 at 12:49 PM EDT
Leerink analyst Geoffrey Porges took Vertex Pharmaceuticals (VRTX) to the woodshed today over sales of its cystic fibrosis drug Orkambi . But he still sees the stock outperforming over the next 12 months.